Literature DB >> 19399891

Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF.

D E Redmond1, J D Elsworth, R H Roth, C Leranth, T J Collier, B Blanchard, K B Bjugstad, R J Samulski, P Aebischer, J R Sladek.   

Abstract

In spite of partial success in treating Parkinson's disease by using ectopically placed grafts of dopamine-producing cells, restoration of the original neuroanatomical circuits, if possible, might work better. Previous evidence of normal anatomic projections from ventral mesencephalic (VM) grafts placed in the substantia nigra (SN) has been limited to neonatal rodents and double grafting or bridging procedures. This study attempted to determine whether injection of a potent growth-promoting factor, glial cell line-derived neurotrophic factor (GDNF), into the target regions or placement of fetal striatal co-grafts in the nigrostriatal pathway might elicit neuritic outgrowth to the caudate nucleus. Four adult St. Kitts green monkeys received embryonic VM grafts into the rostral mesencephalon near the host SN, and injections of adeno-associated virus 2 (AAV2)/GDNF or equine infectious anemia virus (EIAV)/GDNF into the caudate. Three adult monkeys were co-grafted with fetal VM tissue near the SN and fetal striatal grafts (STR) 2.5 mm rostral in the nigrostriatal pathway. Before sacrifice, the striatal target regions were injected with the retrograde tracer Fluoro-Gold (FG). FG label was found in tyrosine hydroxylase-labeled neurons in VM grafts in the SN of only those monkeys that received AAV2/GDNF vector injections into the ipsilateral striatum. All monkeys showed FG labeling in the host SN when FG labeling was injected on the same side. These data show that grafted dopaminergic neurons can extend neurites to a distant target releasing an elevated concentration of GDNF, and suggest that grafted neurons can be placed into appropriate loci for potential tract reconstruction. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399891      PMCID: PMC2881694          DOI: 10.1002/cne.22028

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  36 in total

1.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Authors:  J H Kordower; M E Emborg; J Bloch; S Y Ma; Y Chu; L Leventhal; J McBride; E Y Chen; S Palfi; B Z Roitberg; W D Brown; J E Holden; R Pyzalski; M D Taylor; P Carvey; Z Ling; D Trono; P Hantraye; N Déglon; P Aebischer
Journal:  Science       Date:  2000-10-27       Impact factor: 47.728

2.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.

Authors:  Jeffrey H Kordower; Yaping Chu; Robert A Hauser; Thomas B Freeman; C Warren Olanow
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

4.  Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease.

Authors:  N Déglon; J L Tseng; J C Bensadoun; A D Zurn; Y Arsenijevic; L Pereira de Almeida; R Zufferey; D Trono; P Aebischer
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

5.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

6.  Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys.

Authors:  David N Hovland; Robert B Boyd; Mark T Butt; Jeffery A Engelhardt; Michael S Moxness; Mark H Ma; Maurice G Emery; Nadia B Ernst; Randall P Reed; Jillynne R Zeller; Don M Gash; Donna M Masterman; Beth M Potter; Mary E Cosenza; Ruth M Lightfoot
Journal:  Toxicol Pathol       Date:  2007-08       Impact factor: 1.902

7.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

Authors:  William J Marks; Jill L Ostrem; Leonard Verhagen; Philip A Starr; Paul S Larson; Roy Ae Bakay; Robin Taylor; Deborah A Cahn-Weiner; A Jon Stoessl; C Warren Olanow; Raymond T Bartus
Journal:  Lancet Neurol       Date:  2008-04-02       Impact factor: 44.182

8.  AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons.

Authors:  J D Elsworth; D E Redmond; C Leranth; K B Bjugstad; J R Sladek; T J Collier; S B Foti; R J Samulski; K P Vives; R H Roth
Journal:  Exp Neurol       Date:  2008-02-15       Impact factor: 5.330

9.  Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion.

Authors:  Suzanna M Tatarewicz; Xin Wei; Shalini Gupta; Donna Masterman; Steven J Swanson; Michael S Moxness
Journal:  J Clin Immunol       Date:  2007-07-14       Impact factor: 8.317

10.  Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.

Authors:  Ivar Mendez; Angel Viñuela; Arnar Astradsson; Karim Mukhida; Penelope Hallett; Harold Robertson; Travis Tierney; Renn Holness; Alain Dagher; John Q Trojanowski; Ole Isacson
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

View more
  18 in total

1.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

Review 2.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

Review 3.  Cellular repair in the parkinsonian nonhuman primate brain.

Authors:  Donald Eugene Redmond; Stephanie Weiss; John D Elsworth; Robert H Roth; Dustin R Wakeman; Kimberly B Bjugstad; Timothy J Collier; Barbara C Blanchard; Yang D Teng; Evan Y Synder; John R Sladek
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

4.  Enhancement of polysialic acid expression improves function of embryonic stem-derived dopamine neuron grafts in Parkinsonian mice.

Authors:  Daniela Battista; Yosif Ganat; Abderrahman El Maarouf; Lorenz Studer; Urs Rutishauser
Journal:  Stem Cells Transl Med       Date:  2013-12-05       Impact factor: 6.940

5.  Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF.

Authors:  C Zhang; Y Jin; K S Ziemba; A M Fletcher; B Ghosh; E Truit; D M Yurek; G M Smith
Journal:  Exp Neurol       Date:  2013-10-04       Impact factor: 5.330

6.  Cell intrinsic and extrinsic factors contribute to enhance neural circuit reconstruction following transplantation in Parkinsonian mice.

Authors:  Jessica Kauhausen; Lachlan H Thompson; Clare L Parish
Journal:  J Physiol       Date:  2012-10-08       Impact factor: 5.182

7.  Human neural stem cells survive long term in the midbrain of dopamine-depleted monkeys after GDNF overexpression and project neurites toward an appropriate target.

Authors:  Dustin R Wakeman; D Eugene Redmond; Hemraj B Dodiya; John R Sladek; Csaba Leranth; Yang D Teng; R Jude Samulski; Evan Y Snyder
Journal:  Stem Cells Transl Med       Date:  2014-04-17       Impact factor: 6.940

8.  VGluT2 Expression in Dopamine Neurons Contributes to Postlesional Striatal Reinnervation.

Authors:  Willemieke M Kouwenhoven; Guillaume Fortin; Anna-Maija Penttinen; Clélia Florence; Benoît Delignat-Lavaud; Marie-Josée Bourque; Thorsten Trimbuch; Milagros Pereira Luppi; Alix Salvail-Lacoste; Pascale Legault; Jean-François Poulin; Christian Rosenmund; Raj Awatramani; Louis-Éric Trudeau
Journal:  J Neurosci       Date:  2020-09-14       Impact factor: 6.167

9.  Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model.

Authors:  D Eugene Redmond; Caleb R S McEntire; Joseph P Kingsbery; Csaba Leranth; John D Elsworth; Kimberly B Bjugstad; Robert H Roth; Richard J Samulski; John R Sladek
Journal:  Mol Ther       Date:  2013-08-05       Impact factor: 11.454

10.  Characterization of the stability and bio-functionality of tethered proteins on bioengineered scaffolds: implications for stem cell biology and tissue repair.

Authors:  Ting-Yi Wang; Kiara A F Bruggeman; Rebecca K Sheean; Bradley J Turner; David R Nisbet; Clare L Parish
Journal:  J Biol Chem       Date:  2014-04-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.